Table II.

Clinical trials of anti-glioma chemotherapy drugs.

Clinical trials number	Status	Agent	Phase	Combination therapy	Research purposes
NCT00272870	Terminated	TMZ	I	O6 Benzyl guanine	Overcoming TMZ resistance and hematologic toxicity
NCT05052957	Not yet	TMZ	II	O6 Benzyl guanine	Treatment
	recruiting	Carmustine
NCT00687765	Completed	TMZ	I and II	BSI-201 (PARP-1 inhibitor)	Determining the maximum tolerated dose of BSI-201 and evaluating efficacy
NCT03914742	Recruiting	TMZ	I and II	BGB-290 (PARP inhibitor)	Treatment
NCT03749187	Recruiting	TMZ	I	BGB-290 (PARP inhibitor)	Evaluating the side effects and the optimal dose
NCT00994071	Completed	TMZ	I	ABT-888 (PARP inhibitor)	Treatment
NCT01644955	Completed	Carboplatin	I	Convection-enhanced delivery	Treatment and assessing maximum tolerated dose and toxic effects
NCT03603379	Completed	Doxorubicin	I	Anti-EGFR-immunoliposomes loaded with doxorubicin (C225-ILs-dox)	Pharmacokinetics
NCT00944801	Completed	Doxorubicin	I and II	Pegylated liposomal	Treatment
NCT02766699	Unknow	Doxorubicin	I	EGFR(V)-EDV-Dox	Assessment of safety, tolerability and immunogenicity
NCT02333513	Unknow	Vincristine	-	-	Treatment
NCT03927274	Recruiting	Topotecan	I	Convection-enhanced delivery	Assessing safety and tolerability
NCT02278510	Completed	Topotecan	I	Gadolinium DTPA and convection-enhanced delivery	Treatment
NCT03154996	Completed	Topotecan	I	Gadolinium and convection-enhanced delivery	Treatment

PARP, Poly (ADP-ribose) polymerase; TMZ, temozolomide.